Chemotherapy-Induced Nausea and Vomiting: Advances in Pharmacologic Prevention and Management

Jointly sponsored by the American Academy of CME, Inc and Princeton CME

Target Audience

This activity is designed for oncologists, nurses, and pharmacists specializing in oncology or cancer-related support/quality-of-life care.

Learning Objectives

After completing this activity, participants should be able to:

Describe the relationship to and clinical impact of chemotherapy-induced nausea and vomiting (CINV) on quality of life
Summarize the latest evidence supporting the effectiveness of current guideline-recommended antiemetic prevention and treatment
Assess the efficacy of traditional therapies for CINV
Outline under-addressed problems in controlling CINV and the evidence for approaching these difficult issues
Evaluate the rationale for and the results of current investigational studies in CINV
Implement effective prevention and treatment strategies to improve CINV outcomes

Credit Eligibility

To be eligible for documentation of credit all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: October 18, 2007; Expiration Date: October 18, 2008

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, post-test, and evaluation are available as a click through via the menu at the top of each page of this educational activity.

CME Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of CME, Inc and Princeton CME. The American Academy of CME, Inc is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of CME, Inc designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

To contact the American Academy of CME, Inc, please e-mail dbottinick@academycme.org or call 609-921-6622.

CNE Accreditation

The American Academy of CME, Inc is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The American Academy of CME, Inc designates this activity for 1.0 contact hour.

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-999-07-028-H01).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Grant Support

Supported by an educational grant from Solvay Pharmaceuticals, Inc.

Presenters

Richard J. Gralla, MD
President, New York Lung Cancer Alliance
New York, New York

Mark T. Holdsworth, PharmD, BCOP
Associate Professor of Pharmacy and Pediatrics
College of Pharmacy
University of New Mexico
Albuquerque, New Mexico

Independent Clinical Reviewers

William J. Gradishar, MD, FACP
Professor of Medicine
Director, Breast Medical Oncology
Northwestern University
Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of the American Academy of CME, Inc and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the Academy and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Gralla: Scientific advisory board and Consulting—GlaxoSmithKline, Helsinn, Merck, MGI PHARMA, Schering-Plough, Solvay
Dr. Holdsworth disclosed no relevant financial relationships with any commercial interests.
Dr. Gradishar disclosed no relevant financial relationships with any commercial interests.

Planning Committee Debra Bottinick and Natalie Kirkwood, the American Academy of CME, Inc; Randy Robbin and John Savage, Princeton CME; Rosemary Hodgson, Melissa Berman, and William Kormos, Princeton Media Communications have disclosed they have no relevant financial relationships with any commercial interests.

The American Academy of CME, Inc, and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The faculty will discuss either non-FDA-approved or investigational uses of the following products/devices: olanzepine, gabapentin, aprepitant, palonosetron, and tropisetron.